Shots:
- Merck has reported P-III (STRIDE-13) trial evaluating Capvaxive (21-valent pneumococcal conjugate vaccine) vs PPSV23 in pts (n=882; 2 to <18yrs.) with prior pediatric pneumococcal vaccination & chronic conditions increasing pneumococcal disease risk
- Trial showed that Capvaxive induced immune responses to all 21 serotypes per opsonophagocytic activity (OPA) geometric mean titers (2EP), plus was noninferior to PPSV23 for the 12 shared serotypes, & superior for the 9 unique serotypes at 30 days post-vaccination (1EP); data presented at ESCMID & shared with global health authority
- Capvaxive (single dose) targets Streptococcus pneumoniae serotypes against IPD in adults, incl. 8 unique serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31, 35B)
Ref: Merck | Image: Merck | Press Release
Related News:- Merck Reports Topline P-III (CORALreef Lipids) Trial Data of Enlicitide Decanoate to Treat Hypercholesterolemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
